A Brief Overview of Antipsychotics

Vaidutis Kucinskas*

Department of Human and Medical Genetics, Vilnius University, Lithuania

I

Antipsychotics, a class of medications primarily used to manage psychotic disorders such as schizophrenia and bipolar disorder, play a crucial role in stabilizing individuals' mental health and improving their overall quality of life. ese drugs exert their e ects by modulating neurotransmitter activity in the brain, particularly dopamine and serotonin.

First-generation antipsychotics, also known as typical antipsychotics, paved the way for psychiatric treatment but o en brought about severe side e ects like extrapyramidal symptoms and tardive dyskinesia. While e ective in managing positive symptoms like hallucinations and delusions, their limitations prompted the development of second-generation antipsychotics, or atypical antipsychotics. Atypical antipsychotics o er a more favourable side e ect pro le, reduced risk of movement disorders, and broader e cacy across positive and negative symptoms. Clozapine, for instance, stands out for its e ectiveness in treatment-resistant schizophrenia, despite its association with potential hematological side e ects. Other atypical antipsychotics like risperidone, olanzapine, and aripiprazole have gained popularity for their diverse mechanisms of action and improved tolerability [1].

However, it's important to note that antipsychotic use isn't without

disorders. ese side e ects can impact daily functioning and overall well-being.

C : While some antipsychotics have cognitive-enhancing e ects, others may lead to cognitive dulling or impairment, a ecting memory, attention, and decision-making.

: Prolonged use of antipsychotics, especially rst-generation ones, can lead to tardive dyskinesia, a condition characterized by involuntary movements, o en a ecting the face and limbs.

C : Certain antipsychotics are associated with an increased risk of cardiovascular issues, diabetes, and metabolic syndrome. Regular monitoring and lifestyle management are essential to mitigate these risks [8].

: Abrupt discontinuation of antipsychotics can lead to withdrawal symptoms and potential relapse. Long-term use might also result in a dependence on the medication.

I : Antipsychotic response varies among individuals. Finding the right medication and dosage can be a trial-and-error process, which can be frustrating and time-consuming.

S : Despite advancements in understanding mental health, there can still be stigma associated with taking antipsychotic medication, leading to social isolation and discrimination [9].

In sum, antipsychotics o er signi cant bene ts by alleviating symptoms and improving the lives of individuals with psychotic disorders. However, their use comes with potential drawbacks, including side e ects and challenges that must be carefully managed to ensure the best possible outcomes for patients in their daily lives.

Antipsychotics have revolutionized the eld of psychiatry by providing e ective treatment options for individuals grappling with psychotic disorders. From the pioneering rst-generation antipsychotics to the more advanced second-generation atypical antipsychotics, these medications have addressed both positive and negative symptoms, o ering relief from hallucinations, delusions, and mood uctuations.

While the advent of atypical antipsychotics has brought about improved tolerability and a broader spectrum of action, they are not without their challenges. e management of side e ects such as metabolic disturbances, weight gain, and potential long-term cognitive e ects requires careful consideration and monitoring [10,11].

e journey of antipsychotic development underscores the on-going pursuit of balancing therapeutic bene ts with potential risks. It highlights the importance of a holistic approach to mental health treatment, integrating medication with psychotherapy, social support, and individualized care plans. As our understanding of brain function deepens and new research emerges, the landscape of antipsychotics continues to evolve, promising even more e ective and tailored interventions for individuals on their path to recovery.

References

1. Ngwogu K, Mba I, Ngwogu A (2012) Glycaemic control amongst diabetic mellitus patients in Umuahia Metroppolis, Abia State, Nigeria. IJBAIR 1: 98-104.
2. Emeka PM, Al Mukalaf A, Al Helal H, Khan TM, Almukalf MA (2017) Prevalence of poor glycemic and blood pressure control and pattern of drug use among primary health-care outpatients in Al Ahsa Saudi Arabia. Int J Health Sci 11: 38.
3. Bonsembiante L, Targher G, Mafeis C (2021) Type 2 Diabetes and Dietary Carbohydrate Intake of Adolescents and Young Adults: What Is the Impact of Di erent Choices? Nutrients 13: 3344.
4. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, et al. (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300: 1140-1142.
5. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-6.
6. Kamuhabwa AR, Charles E (2014) Predictors of poor glycemic control in type 2 diabetic patients attending public hospitals in Dar es Salaam. Drug Healthc Patient Saf 6: 155.
7. Onodugo OD, Ezeala-Adikaibe BA, Anyim OB, Onodugo P, Anyim IN, et al. (2019) Glycemic control among medical outpatients in Enugu: a cross sectional survey. J Diab Mellitus 9: 50.
8. Blair M (2016) Diabetes Mellitus Review. Urologic nursing.36: 27-36.
9. Tino S, Wekesa C, Kamacooko O, Makhoba A, Mwebaze R, et al. (2019) Predictors of loss to follow up among patients with type 2 diabetes mellitus attending a private not for pro t urban diabetes clinic in Uganda - a descriptive retrospective study. BMC Health Serv Res 19: 598.
10. Kibirige D, Atuhe D, Sebunya R, Mwebaze R (2014) Suboptimal glycaemic and blood pressure control and screening for diabetic complications in adult ambulatory diabetic patients in Uganda: a retrospective study from a developing country. J Diabetes Metab Disord 13: 1-7.
11. Gunda DW, Bandali HA, Malindisa EK, Kidenya BR (2020) Use of HBA1c and potentiality of gender, missed medication and fasting glucose in the prediction of poor glycemic control in resource-limited setting; a clinic-based case-control study. PAMJ-One Health 2.